Pruritic Diseases and Secondary Changes Flashcards
Urticaria most symptomatic
Early lesion and small superficial wheals
How to treat urticaria?
Antihistamines - decrease pruritus - leads to resolution of wheals
Assessment that should be performed in all patient’s with itch?
Dermatographism (exaggerated wheal development) mark the skin to see if a wheal develops
Factors that contribute to itch in atopic dermatitis
Epidermal hyper-innervation and central sensitization
What is nemolizumab
anti-IL-31 receptor A medication used to decrease itch
Scabies itch starts when
- 3-6 weeks after the initial infection
- within days of subsequent
Immune response during scabies targets
Mites
Eggs
Scybala ( fecal matter)
CTCL and itch
> 60% of patients have itch
frequency intensifies at later stages i.e Sezary Syndrome
What cytokine is associated with itch in CTCL
IL-31
Nemolizumab is an antibody against the IL-31 RA
CTCL itch treatment options (experimental)
Nemolizumab
Mogamulizumab
gabapentin 900-2400 mg/day (split into 3 doses)
Mirtazepine 7.5 -15 mg
Naltrexone 50-150 mg/day
Aprepitant (neurokinin 1 blocker)
Prurigo Nodularis
Dome shaped, firm, hyperpigmented papulonodules +/- central crust/scale/erosion
Prurigo Nodularis Distribution
Symmetrically along the extremities (typically extensor surface)
Butterfly sign with sparing of the upper mid back
Also spares flexural areas, face and groin
Prurigo Nodularis Causes
chronic repetitive scratching/picking due to a pruritic systemic or dermatological or psychogenic diseaese
Prurigo Nodularis Epidemiology
Middle aged adult with dermatologic/psychiatric diseases
occasionally in children with atopic dermatitis
Prurigo Nodularis Pathology
Epidermal hyperplasia
Compact hyperkeratosis
Vertically arranged collagen fibers
increased number of fibroblasts and capillaris
perivascular/ interstitial mixed inflammatory infiltrate
increased dermal nerve fibers
decreased epidermal nerve fibers